Latest Curis Inc (CRIS) Headlines Curis to Pres
Post# of 68
Posted On: 03/13/2014 7:07:38 AM
Latest Curis Inc (CRIS) Headlines
Curis to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.
Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.
Curis to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 6:14AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the Cowen and Company 34 Annual Health Care Conference at 4:50 p.m. ET on March 3, 2014, in Boston.
Small Business Owners Heading Into Retirement May Be Underestimating Value of Their Business: Scotiabank Study
Marketwire Canada - Tue Feb 25, 5:30AM CST
According to a recent Scotiabank poll, a quarter of Canada's small business owners (26%) expect their RRSP contributions to be their primary source of income in retirement, followed by proceeds from selling their business (17%), their savings (15%) and government pensions (8%).
Stock to Watch: Curis Up 5.4% (CRIS)
Comtex SmarTrend(R) - Thu Feb 20, 12:46PM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.4% to $3.13 on 1.2x average daily volume. Thus far today, Curis has traded 564,000 shares, vs. average volume of 484,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.7%) and outperformed the S&P 500 (5.4% to the S&P's 0.6%) during today's trading.
Curis Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Feb 20, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported its financial results for the fourth quarter and year ended December 31, 2013.
Curis to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire - Wed Feb 19, 3:15PM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the RBC Capital Markets Global Healthcare Conference at 1:35 p.m. ET on February 26, 2014, in New York City.
Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014
GlobeNewswire - Thu Feb 13, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Thursday, February 20, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Standard Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427 as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2013.
Curis to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Leerink Global Healthcare Conference at 10:40 a.m. ET on February 12, 2014, in New York City.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Dec 20, 7:53AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
This Week in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 14, 11:05AM CST
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Why Curis Inc. Shares Tanked
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 09, 4:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Curis , a clinical-stage biopharmaceutical...
Curis Down 14.0%, Shares Slide into the Red (CRIS)
Comtex SmarTrend(R) - Mon Dec 09, 11:42AM CST
Curis (NASDAQ:CRIS) is one of today's worst performing low-priced stocks, down 14.0% to $2.95 on 1.7x average daily volume. Thus far today, Curis has traded 1.2 million shares, vs. average volume of 659,000 shares per day. The stock has underperformed the Dow (-14.0% to the Dow's 0.1%) and underperformed the S&P 500 (-14.0% to the S&P's 0.3%) during today's trading.
Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting
GlobeNewswire - Mon Dec 09, 10:00AM CST
CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity
Global Stem Cell Anticancer Therapeutics Market Forecasts Report to 2016
M2 - Fri Dec 06, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9dnj7/global_stem_cell) has announced the addition of the "Global Stem Cell Anticancer Therapeutics Market Forecasts Report to 2016" report to their offering. One of the main factors driving the market is the significant increase in the drug pipeline targeting cancer stem cells. These cells have the capacity to divide and give rise to new cancer stem cells through a process called self-renewal and have the ability to change into the other cells that form the bulk of the tumour. One of the main trends witnessed in the Global Stem Cell Anticancer Therapeutics market is the increase in industry activities. Cancer therapy apart from usual radiotherapy has entered into new era of stem cell therapy. Research is going on to recognize and isolate cancer stem cells with those of normal stem cells by using cell surface antigen markers. More intricate research work is needed to carry out reveal signalling pathways and functioning of different genes in process of carcinogenesis during cancer stem cell differentiation. This would help in development of new therapies which would help in elimination of eventual disease and recurrence. This trend is expected to have a strong impact on the growth of the market. Further, the report states that one of the main challenges is the lack of awareness in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in stem cell products and therapies. The key vendors dominating this space include: - Celgene Corp. - Curis Inc. - Exelixis Inc. - Gamida Cell Ltd. - Lonza Group - Merck & Co. Inc. - OncoMed Pharmaceuticals Inc. - Pfizer Inc. - Roche Holding AG - Teva Pharmaceutical Industries Ltd. - Verastem Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Introduction 04. Market Research Methodology 05. Scope of the Report 06. Stem Cells 07. Market Landscape 08. Geographical Segmentation 09. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/b9..._stem_cell
Curis to Present at the Oppenheimer 24th Annual Healthcare Conference
GlobeNewswire - Wed Dec 04, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Oppenheimer 24 Annual Healthcare Conference at 2:45 p.m. ET on December 11, 2013, in New York City.
Curis, Inc. (CRIS) Soars: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 6:51AM CST
Curis, Inc. was a big mover last session as its shares surged around 12% on the day.
Curis to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 26, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:
Traders Get Bullish on Shares of Curis, Shares Up 8.9% (CRIS)
Comtex SmarTrend(R) - Mon Nov 25, 11:45AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 8.9% to $3.07 on 1.0x average daily volume. Thus far today, Curis has traded 641,000 shares, vs. average volume of 628,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's 0.2%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
Curis to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.
Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.
Curis to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 6:14AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the Cowen and Company 34 Annual Health Care Conference at 4:50 p.m. ET on March 3, 2014, in Boston.
Small Business Owners Heading Into Retirement May Be Underestimating Value of Their Business: Scotiabank Study
Marketwire Canada - Tue Feb 25, 5:30AM CST
According to a recent Scotiabank poll, a quarter of Canada's small business owners (26%) expect their RRSP contributions to be their primary source of income in retirement, followed by proceeds from selling their business (17%), their savings (15%) and government pensions (8%).
Stock to Watch: Curis Up 5.4% (CRIS)
Comtex SmarTrend(R) - Thu Feb 20, 12:46PM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.4% to $3.13 on 1.2x average daily volume. Thus far today, Curis has traded 564,000 shares, vs. average volume of 484,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.7%) and outperformed the S&P 500 (5.4% to the S&P's 0.6%) during today's trading.
Curis Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Feb 20, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported its financial results for the fourth quarter and year ended December 31, 2013.
Curis to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire - Wed Feb 19, 3:15PM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the RBC Capital Markets Global Healthcare Conference at 1:35 p.m. ET on February 26, 2014, in New York City.
Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014
GlobeNewswire - Thu Feb 13, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Thursday, February 20, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Standard Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427 as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2013.
Curis to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Leerink Global Healthcare Conference at 10:40 a.m. ET on February 12, 2014, in New York City.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Dec 20, 7:53AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
This Week in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 14, 11:05AM CST
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Why Curis Inc. Shares Tanked
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 09, 4:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Curis , a clinical-stage biopharmaceutical...
Curis Down 14.0%, Shares Slide into the Red (CRIS)
Comtex SmarTrend(R) - Mon Dec 09, 11:42AM CST
Curis (NASDAQ:CRIS) is one of today's worst performing low-priced stocks, down 14.0% to $2.95 on 1.7x average daily volume. Thus far today, Curis has traded 1.2 million shares, vs. average volume of 659,000 shares per day. The stock has underperformed the Dow (-14.0% to the Dow's 0.1%) and underperformed the S&P 500 (-14.0% to the S&P's 0.3%) during today's trading.
Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting
GlobeNewswire - Mon Dec 09, 10:00AM CST
CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity
Global Stem Cell Anticancer Therapeutics Market Forecasts Report to 2016
M2 - Fri Dec 06, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9dnj7/global_stem_cell) has announced the addition of the "Global Stem Cell Anticancer Therapeutics Market Forecasts Report to 2016" report to their offering. One of the main factors driving the market is the significant increase in the drug pipeline targeting cancer stem cells. These cells have the capacity to divide and give rise to new cancer stem cells through a process called self-renewal and have the ability to change into the other cells that form the bulk of the tumour. One of the main trends witnessed in the Global Stem Cell Anticancer Therapeutics market is the increase in industry activities. Cancer therapy apart from usual radiotherapy has entered into new era of stem cell therapy. Research is going on to recognize and isolate cancer stem cells with those of normal stem cells by using cell surface antigen markers. More intricate research work is needed to carry out reveal signalling pathways and functioning of different genes in process of carcinogenesis during cancer stem cell differentiation. This would help in development of new therapies which would help in elimination of eventual disease and recurrence. This trend is expected to have a strong impact on the growth of the market. Further, the report states that one of the main challenges is the lack of awareness in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in stem cell products and therapies. The key vendors dominating this space include: - Celgene Corp. - Curis Inc. - Exelixis Inc. - Gamida Cell Ltd. - Lonza Group - Merck & Co. Inc. - OncoMed Pharmaceuticals Inc. - Pfizer Inc. - Roche Holding AG - Teva Pharmaceutical Industries Ltd. - Verastem Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Introduction 04. Market Research Methodology 05. Scope of the Report 06. Stem Cells 07. Market Landscape 08. Geographical Segmentation 09. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/b9..._stem_cell
Curis to Present at the Oppenheimer 24th Annual Healthcare Conference
GlobeNewswire - Wed Dec 04, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Oppenheimer 24 Annual Healthcare Conference at 2:45 p.m. ET on December 11, 2013, in New York City.
Curis, Inc. (CRIS) Soars: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 6:51AM CST
Curis, Inc. was a big mover last session as its shares surged around 12% on the day.
Curis to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 26, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:
Traders Get Bullish on Shares of Curis, Shares Up 8.9% (CRIS)
Comtex SmarTrend(R) - Mon Nov 25, 11:45AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 8.9% to $3.07 on 1.0x average daily volume. Thus far today, Curis has traded 641,000 shares, vs. average volume of 628,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's 0.2%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
(0)
(0)Curis Inc. (CRIS) Stock Research Links
Scroll down for more posts ▼